Active	Status	Sponsor type	Region	Phase	Filter
18 Active 4 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

18 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Korczowski, Bartosz
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2	Recruiting	3	612	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial	Recruiting	3	150	Europe, Canada, US, RoW	SerpinPC, Activated Protein C (APC) inhibitor	ApcinteX Ltd, Centessa Pharmaceuticals plc	Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor	11/28	11/28
NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)	Recruiting	3	120	Europe, Canada, Japan, US, RoW	Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002	Takeda, Takeda Development Center Americas, Inc.	Crohn's Disease (CD)	11/24	11/24
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Recruiting	3	778	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Crohn's Disease	11/24	12/26
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
NCT04701411 / 2020-003193-48: A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease	Recruiting	3	20	Europe, Japan, RoW	Darvadstrocel, Cx601	Takeda, Takeda Development Center Americas, Inc.	Crohn's Disease, Complex Perianal Fistula	06/25	12/25
MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)	Active, not recruiting	3	121	Europe, Canada, Japan, US, RoW	Vedolizumab, MLN0002, ENTYVIO, KYNTELES	Takeda, Takeda Development Center Americas, Inc.	Colitis, Ulcerative	08/25	08/25
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis	Recruiting	3	60	Europe, Canada, Japan, US, RoW	Mirikizumab IV, LY3074828, Mirikizumab SC	Eli Lilly and Company	Ulcerative Colitis	07/26	03/27
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease	Recruiting	3	90	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company, Eli Lilly and Company	Crohn's Disease	07/27	10/27
SHINE-ON, NCT04844606: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease	Recruiting	3	150	Europe, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease	07/30	07/30
NCT05442567 / 2021-000630-34: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)	Recruiting	3	240	Europe, Canada, Japan, US, RoW	Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention	Takeda, Takeda Development Center Americas, Inc.	Ulcerative Colitis, Crohn's Disease	08/31	08/31
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease	Recruiting	2	268	Europe, Canada, Japan, US, RoW	TAK-279, Zasocitinib, Placebo	Takeda	Crohn's Disease	09/26	07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis	Recruiting	2	207	Europe, Canada, Japan, US, RoW	TAK-279, Zasocitinib, Placebo	Takeda	Ulcerative Colitis	09/26	08/27
NCT02616302 / 2014-004506-15: A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old	Recruiting	2	70	Europe, Canada, US, RoW	Dexlansoprazole, Dexilant	Takeda	Gastroesophageal Reflux Disease (GERD)	10/27	10/27
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet	Active, not recruiting	2	357	Europe, Canada, US	TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar	Takeda	Celiac Disease	05/25	05/25
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B	Recruiting	2	120	Europe, Canada, US, RoW	SerpinPC, Activated Protein C (APC) inhibitor	ApcinteX Ltd, Centessa Pharmaceuticals plc	Hemophilia A, Hemophilia B	03/26	06/26
NCT02615184 / 2014-004507-73: A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old	Recruiting	2	76	Europe, Canada, US, RoW	Dexlansoprazole, Dexilant	Takeda	Erosive Esophagitis	10/27	10/27
PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention	Recruiting	N/A	200	Europe, Canada, US, RoW	No Intervention	ApcinteX Ltd, Centessa Pharmaceuticals plc	Hemophilia A, Hemophilia B	11/24	11/24
Vermeire, Séverine
No trials found